The mitochondrial K(ATP) channel and cardioprotection
- PMID: 12607710
- DOI: 10.1016/s0003-4975(02)04689-1
The mitochondrial K(ATP) channel and cardioprotection
Abstract
Adenosine triphosphate (ATP)-sensitive potassium (K(ATP)) channels allow coupling of membrane potential to cellular metabolic status. Two K(ATP) channel subtypes coexist in the myocardium, with one subtype located in the sarcolemma (sarcK(ATP)) membrane and the other in the inner membrane of the mitochondria (mitoK(ATP)). The K(ATP) channels can be pharmacologically modulated by a family of structurally diverse agents of varied potency and selectivity, collectively known as potassium channel openers and blockers. Sufficient evidence exists to indicate that the K(ATP) channels and, in particular, the mitoK(ATP) channels play an important role both as a trigger and an effector in surgical cardioprotection. In this review, the biochemistry and surgical specificity of the K(ATP) channels are examined.
Similar articles
-
Mitochondrial ATP-sensitive potassium channels in surgical cardioprotection.Arch Biochem Biophys. 2003 Dec 15;420(2):237-45. doi: 10.1016/j.abb.2003.06.003. Arch Biochem Biophys. 2003. PMID: 14654062 Review.
-
Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection.Circulation. 2000 May 23;101(20):2418-23. doi: 10.1161/01.cir.101.20.2418. Circulation. 2000. PMID: 10821820
-
Contribution of both the sarcolemmal K(ATP) and mitochondrial K(ATP) channels to infarct size limitation by K(ATP) channel openers: differences from preconditioning in the role of sarcolemmal K(ATP) channels.Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):226-32. doi: 10.1007/s002100100448. Naunyn Schmiedebergs Arch Pharmacol. 2001. PMID: 11521165
-
Minoxidil opens mitochondrial K(ATP) channels and confers cardioprotection.Br J Pharmacol. 2004 Jan;141(2):360-6. doi: 10.1038/sj.bjp.0705613. Epub 2003 Dec 22. Br J Pharmacol. 2004. PMID: 14691056 Free PMC article.
-
ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart.Curr Vasc Pharmacol. 2003 Oct;1(3):251-8. doi: 10.2174/1570161033476646. Curr Vasc Pharmacol. 2003. PMID: 15320472 Review.
Cited by
-
Mitochondria-targeting particles.Nanomedicine (Lond). 2014 Nov;9(16):2531-43. doi: 10.2217/nnm.14.161. Nanomedicine (Lond). 2014. PMID: 25490424 Free PMC article. Review.
-
Comparison of the Effects of Blood Cardioplegia and Del Nido Cardioplegia on Postoperative Intensive Care Needs, Drainage, and Renal Functions in Patients Undergoing Isolated Coronary Artery Bypass.Braz J Cardiovasc Surg. 2025 Jun 4;40(4):e20240237. doi: 10.21470/1678-9741-2024-0237. Braz J Cardiovasc Surg. 2025. PMID: 40464404 Free PMC article.
-
Commentary: A (Mito)SNO storm to protect the heart.JTCVS Open. 2021 Aug 20;8:355-356. doi: 10.1016/j.xjon.2021.08.022. eCollection 2021 Dec. JTCVS Open. 2021. PMID: 36004195 Free PMC article. No abstract available.
-
Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium channels.J Physiol Biochem. 2014 Jun;70(2):425-32. doi: 10.1007/s13105-014-0320-9. Epub 2014 Feb 18. J Physiol Biochem. 2014. PMID: 24535716
-
Cardiopulmonary bypass and oxidative stress.Oxid Med Cell Longev. 2015;2015:189863. doi: 10.1155/2015/189863. Epub 2015 Feb 4. Oxid Med Cell Longev. 2015. PMID: 25722792 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources